Last reviewed · How we verify

Escitalopram (Lexapro) — Competitive Intelligence Brief

Escitalopram (Lexapro) (Escitalopram (Lexapro)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry / Neurology.

marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Escitalopram (Lexapro) (Escitalopram (Lexapro)) — University of Rochester. Escitalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Escitalopram (Lexapro) TARGET Escitalopram (Lexapro) University of Rochester marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)
Lexapro escitalopram Generic (originally Lundbeck/Forest) marketed Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin (5-HT) reuptake transporter 2002-08-14
Prozac fluoxetine Eli Lilly and Company marketed Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin reuptake transporter 1987-12-29
citalopram (celexa) citalopram (celexa) Sunnybrook Health Sciences Centre marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)
escitalopram and sertraline escitalopram and sertraline Oregon Health and Science University marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)
Lexapro (escitalopram) Lexapro (escitalopram) St. Luke's-Roosevelt Hospital Center marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)
placebo + fluoxetine placebo + fluoxetine University of Florida marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

  1. University of Texas Southwestern Medical Center · 3 drugs in this class
  2. Johns Hopkins University · 2 drugs in this class
  3. GlaxoSmithKline · 2 drugs in this class
  4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
  5. Guangdong Provincial People's Hospital · 1 drug in this class
  6. Janssen Research & Development, LLC · 1 drug in this class
  7. Medical University of Vienna · 1 drug in this class
  8. Massachusetts General Hospital · 1 drug in this class
  9. Fundació Sant Joan de Déu · 1 drug in this class
  10. Centre Hospitalier Universitaire Dijon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Escitalopram (Lexapro) — Competitive Intelligence Brief. https://druglandscape.com/ci/escitalopram-lexapro. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: